Carregant...
Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases
Brain metastases (BMs) are the most common cause of malignant central nervous system (CNS) tumors in adults. In the recent past, patients with BMs were excluded from clinical trials, but now, with the advent of new biological and immunological drugs, their inclusion is more common. In the last era r...
Guardat en:
| Publicat a: | Transl Lung Cancer Res |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5233872/ https://ncbi.nlm.nih.gov/pubmed/28149758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2016.11.02 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|